News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline’s Prescription-Strength Fish Oil Drug, Lovaza Fails in Atrial Fibrillation Study
November 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO, Nov 15 (Reuters) - Taking a high dose of fish oil does not prevent symptoms of atrial fibrillation, a common heart rhythm problem that can cause strokes, U.S. researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
GlaxoSmithKline
MORE ON THIS TOPIC
Immunology and inflammation
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
September 10, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Cullinan, Taiho’s NSCLC Hopeful Shows ‘Strong Activity,’ Clearing Road to FDA
September 10, 2025
·
2 min read
·
Tristan Manalac
Podcast
Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More
September 10, 2025
·
1 min read
·
Jef Akst
Lung cancer
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC
September 9, 2025
·
2 min read
·
Tristan Manalac